A61K 31/504
Forming part of bridged ring systems
Official title: forming part of bridged ring systems
A61K31/504 (Forming part of bridged ring systems) appears on 16 US grants and 65 published applications in this corpus.
Search patents in A61K- Granted patents
- 16
- Published applications
- 65
- Assignees
- 34
- Inventors
- 293
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 2 |
| 2016 | 1 | 3 |
| 2017 | 2 | 2 |
| 2018 | 2 | 1 |
| 2019 | 3 | 1 |
| 2020 | 0 | 2 |
| 2021 | 1 | 2 |
| 2022 | 0 | 0 |
| 2023 | 1 | 2 |
| 2024 | 0 | 7 |
| 2025 | 1 | 17 |
| 2026 | 2 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Macrocyclic compounds, compositions, and methods of using thereof9 Jun 2026US 12,649,750 B2Genzyme Corporation
- Macrocyclic compounds, compositions, and methods of using thereof12 May 2026US 12,624,051 B2Genzyme Corporation
- Macrocyclic derivative and use thereof4 Nov 2025US 12,458,647 B2Guangzhou Joyo Pharmatech Co., Ltd
- Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer26 Sep 2023US 11,766,433 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer20 Apr 2021US 10,980,806 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Cell proliferation modulators and uses thereof1 Oct 2026US 2026/0294925 A1Kumquat Biosciences Inc.
- Ras inhibitors1 Oct 2026US 2026/0297112 A1Revolution Medicines, Inc.
- Compounds capable of modulating gpr6524 Sep 2026US 2026/0285863 A1Pathios Therapeutics Limited
- Ras and prmt5 inhibitors combination therapy17 Sep 2026US 2026/0272921 A1Erasca, Inc.
- Compositions for inducing ras gtp hydrolysis and uses thereof3 Sep 2026US 2026/0256780 A1Revolution Medicines, Inc.
Most cited
By later US patents
- Inhibitors of farnesyl-protein transferase12US 6,103,723 AMerck & Co., Inc. · 2000
- Inhibitors of Akt activity10US 6,960,584 B2Merck & Co., Inc. · 2005
- Macrocyclic inhibitors of flaviviridae viruses6US 9,090,653 B2Gilead Sciences, Inc. · 2015
- Macrocyclic pyridazinone derivatives5US 10,064,861 B2Merck Patent GmbH · 2018
- Pyridazinone compounds and uses thereof2US 10,364,226 B2Alios BioPharma, Inc. · 2019